Skip to main content

Vogenx, Inc.

corporate_fare Company Profile

Vogenx, Inc.

VOGX·NASDAQ·Life Sciences·CIK 0001903784

Vogenx, Inc. is a clinical-stage drug development company focused on creating treatments for metabolic conditions, specifically post-bariatric hypoglycemia (PBH) and gastroparesis. The company's product pipeline includes drug candidates such as Mizagliflozin and VGX-2857. Additionally, Vogenx, Inc. is developing VGX-001, which is a human monoclonal antibody intended for the treatment of type 1 diabetes (T1D). The company's operations are based in Raleigh, North Carolina, where it was incorporated in 2021. Vogenx, Inc. serves healthcare providers, physicians, and third-party payors within the United States market.

Vogenx, Inc. (NASDAQ:VOGX) is a publicly traded company in the Life Sciences sector. Wiseek monitors VOGX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Vogenx Prices $81.25M IPO at $13.00/Share, Lists on Nasdaq
Browse all tickers starting with V →
$12.69 -0.31% today
Live data · 2026-08-12 22:55 UTC · After hours

show_chartPrice Chart

Loading chart...

feed VOGX - Latest Insights

VOGX
Aug 12, 2026, 4:24 PM EDT
Filing Type: 424B4
Importance Score:
8
Vogenx Prices $81.25M IPO at $13.00/Share, Lists on Nasdaq
Price at Filing: $12.69
Real-time Price: $12.69 info
Change: $0 (0%) info
Market Cap: N/A info
Sentiment: Neutral
View Wiseek Article